Shiven Kapur
Eli Lilly and Company
Dr. Shiven Kapur completed his PhD in Chemistry and postdoc in Bioengineering and Medicine at Stanford University before joining Lilly in 2016. He is a Principal Research Scientist at the Lilly Innovation Center in Cambridge, MA as part of the Bioproduct Research and Development group. He is leading efforts to understand and overcome the limitations to subcutaneous delivery of biologics, via the development of a multi-faceted platform to deconvolute the impact of molecule, formulation and device parameters on SQ performance. One of his areas of focus has been to develop and deploy novel preclinical and clinical tools and models that can help us understand and derisk injections site reactions, which represents an understudied and challenging problem that impacts biotherapeutic development not only at Lilly but, biologics in general. These approaches have been successfully deployed across Lilly’s biotherapeutic portfolio. | Shiven Kapur, PhD | Principal Research Scientist, Bioproduct Research and Development, Eli Lilly and Company
Appearances
DateMarch 25, 2022Upon subcutaneous (SQ) injection of therapeutic drugs, a local inflammatory reaction, commonly referred to as an injection site reaction (ISR), may develop at the injection site. ISRs are characterized by one or more of the following, erythema, edema, pruritus, pain, and induration…Speaker
Eli Lilly and CompanyFreeStandard Price
